HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.

Abstract
It is believed that growth of castration resistant prostate cancer (CRPC) cells is enabled by sensitization to minimal residual post-castrate androgen due to overexpression of the androgen receptor (AR). Evidence is derived from androgen-induced colony formation in the absence of cell-secreted factors or from studies involving forced AR overexpression in hormone-dependent cells. On the other hand, standard cell line models established from CRPC patient tumors (e.g., LNCaP and VCaP) are hormone-dependent and require selection pressure in castrated mice to re-emerge as CRPC cells and the resulting tumors then tend to be insensitive to the androgen antagonist enzalutamide. Therefore, we examined established CRPC model cells produced by castration of mice bearing hormone-dependent cell line xenografts including CRPC cells overexpressing full-length AR (C4-2) or co-expressing wtAR and splice-variant AR-V7 that is incapable of ligand binding (22Rv1). In standard colony formation assays, C4-2 cells were shown to be androgen-dependent and sensitive to enzalutamide whereas 22Rv1 cells were incapable of colony formation under identical conditions. However, both C4-2 and 22Rv1 cells formed colonies in conditioned media derived from the same cells or from HEK293 fibroblasts that were proven to lack androgenic activity. This effect was (i) not enhanced by androgen, (ii) insensitive to enzalutamide, (iii) dependent on AR (in C4-2) and on AR-V7 and wtAR (in 22Rv1) and (iv) sensitive to inhibitors of several signaling pathways, similar to androgen-stimulation. Therefore, during progression to CRPC in vivo, coordinate cellular changes accompanying overexpression of AR may enable cooperation between hormone-independent activity of AR and actions of cellular secretory factors to completely override androgen-dependence and sensitivity to drugs targeting hormonal factors.
AuthorsMugdha Patki, Yanfang Huang, Manohar Ratnam
JournalBiochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 476 Issue 2 Pg. 69-74 (07 22 2016) ISSN: 1090-2104 [Electronic] United States
PMID27179779 (Publication Type: Journal Article)
CopyrightCopyright © 2016 Elsevier Inc. All rights reserved.
Chemical References
  • Androgen Antagonists
  • Androgen Receptor Antagonists
  • Androgens
  • Antineoplastic Agents
  • Benzamides
  • Nitriles
  • Receptors, Androgen
  • Phenylthiohydantoin
  • enzalutamide
Topics
  • Androgen Antagonists (pharmacology)
  • Androgen Receptor Antagonists (pharmacology)
  • Androgens (metabolism)
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Benzamides
  • Cell Line, Tumor
  • HEK293 Cells
  • Humans
  • Male
  • Mice
  • Nitriles
  • Phenylthiohydantoin (analogs & derivatives, pharmacology)
  • Prostate (drug effects, metabolism, pathology)
  • Prostatic Neoplasms, Castration-Resistant (drug therapy, genetics, metabolism, pathology)
  • Receptors, Androgen (genetics, metabolism)
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: